Pappas Capital

Pappas Capital is a global venture capital and commercial development firm investing in next-generation life science, agriculture, and technology companies. With over 31 years of experience, the firm has invested in more than 100 companies across the United States, Canada, and Asia, focusing on a wide range of human diseases. Their portfolio includes groundbreaking therapies for conditions such as melanoma, ovarian cancer, and hemophilia, which have collectively treated tens of thousands of patients worldwide and generated billions in revenue.

The firm operates through three main business units: Pappas Ventures, its flagship life science venture arm; Specialized Fund Management, where it creates and manages custom-tailored investment vehicles; and Translational Medicine, where it partners with research universities to accelerate the development of their scientific discoveries and inventions. This structure allows Pappas Capital to provide comprehensive support to its portfolio companies, from initial funding to commercialization.

Pappas Capital's expert team of investment professionals offers valuable insight and guidance to help drive success across their diverse portfolio. Their deep understanding of the drug development process enables management teams to provide insightful guidance and craft effective clinical and regulatory strategies. The firm also endeavors to accelerate the progress of its companies by leveraging its extensive professional network, fostering innovation and growth within the life sciences sector.